down arrow

Glaukos Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3773221029
USD
108.85
1.39 (1.29%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

107.44110.02

52 Week

73.16163.71
Valuation
Technical
Day's Volume

CASH

159.58 k

Shareholding (Mar 2025)

FII

11.54%

Held by 152 FIIs

DII

24.56%

Held by 72 DIIs

Promoter

0.01%

How big is Glaukos Corp.?

22-Jun-2025

As of Jun 18, Glaukos Corp. has a market capitalization of $5.71 billion, with net sales of $404.52 million and a net profit of -$123.69 million over the latest four quarters. Shareholder's funds are $766.93 million, and total assets amount to $1.04 billion.

As of Jun 18, Glaukos Corp. has a market capitalization of 5,705.99 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 404.52 million for the latest four quarters. During the same period, Glaukos Corp. experienced a net profit of -123.69 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 766.93 million and total assets amounting to 1,036.15 million.

Read More

What does Glaukos Corp. do?

22-Jun-2025

Glaukos Corporation is an ophthalmic medical technology company specializing in glaucoma treatments, with recent net sales of $107 million and a market cap of approximately $5.7 billion. The company is currently operating at a loss, with a net profit of -$18 million.

Overview:<BR>Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products and procedures for the treatment of glaucoma, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 107 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 5,705.99 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.39<BR>- Return on Equity: -15.86%<BR>- Price to Book: 7.47<BR><BR>Contact Details:<BR>- Address: 229 Avenida Fabricante, SAN CLEMENTE CA: 92672-7531<BR>- Tel: 1 949 3679600<BR>- Fax: 1 949 3679984<BR>- Website: http://www.glaukos.com/

Read More

Who are in the management team of Glaukos Corp.?

22-Jun-2025

As of March 2022, Glaukos Corp.'s management team includes Dr. William Link (Independent Chairman), Mr. Thomas Burns (President and CEO), and several independent directors: Dr. Gilbert Kliman, Mr. Mark Foley, Mr. David Hoffmeister, Mr. Marc Stapley, and Ms. Aimee Weisner. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Glaukos Corp. includes the following individuals:<BR><BR>- Dr. William Link, who serves as the Independent Chairman of the Board.<BR>- Mr. Thomas Burns, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Gilbert Kliman, who is a Director.<BR>- Mr. Mark Foley, who is an Independent Director.<BR>- Mr. David Hoffmeister, who is also an Independent Director.<BR>- Mr. Marc Stapley, another Independent Director.<BR>- Ms. Aimee Weisner, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Glaukos Corp. overvalued or undervalued?

20-Sep-2025

As of May 7, 2020, Glaukos Corp. is considered overvalued and risky due to its high Price to Book Value of 6.96, negative EV to EBIT and EV to EBITDA ratios, low ROCE and ROE, and poor stock performance compared to its peers and the S&P 500.

As of 7 May 2020, the valuation grade for Glaukos Corp. moved from attractive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued given its high Price to Book Value of 6.96 and negative EV to EBIT and EV to EBITDA ratios of -49.44 and -80.62, respectively. Additionally, the latest ROCE and ROE are concerning at -21.81% and -15.86%, suggesting inefficiencies in generating returns.<BR><BR>In comparison to its peers, Glaukos Corp. has a significantly lower P/E ratio of -56.81, while Masimo Corp. shows a P/E of 179.74, and Globus Medical, Inc. presents a more favorable P/E of 18.37, highlighting the disparity in valuation. The company's recent stock performance has been underwhelming, with a year-to-date return of -42.75% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that Glaukos Corp. is currently overvalued in the market.

Read More

Is Glaukos Corp. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Glaukos Corp. is in a mildly bearish trend, with mixed technical indicators and underperformance compared to the S&P 500, showing returns of -1.67% over the past month and -34.77% over the past year.

As of 31 October 2025, the technical trend for Glaukos Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, suggesting some underlying strength. However, both the Bollinger Bands and KST are bearish on the weekly and monthly, reinforcing the bearish sentiment. Moving averages are mildly bearish on the daily timeframe.<BR><BR>In terms of performance, Glaukos Corp. has underperformed the S&P 500 over the past month and year, with returns of -1.67% and -34.77%, respectively, compared to the S&P 500's 1.92% and 19.89%. This highlights the stock's current weakness relative to the broader market.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Operating Profit of 17.44%, the company declared Very Positive results in Jun 25

  • OPERATING CASH FLOW(Y) Highest at USD -20.62 MM
  • NET PROFIT(HY) Higher at USD -37.8 MM
  • ROCE(HY) Highest at -12.98%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,272 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.36

stock-summary
Return on Equity

-12.13%

stock-summary
Price to Book

6.89

Revenue and Profits:
Net Sales:
124 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.76%
0%
20.76%
6 Months
19.67%
0%
19.67%
1 Year
-21.28%
0%
-21.28%
2 Years
70.05%
0%
70.05%
3 Years
127.62%
0%
127.62%
4 Years
170.3%
0%
170.3%
5 Years
54.99%
0%
54.99%

Glaukos Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Glaukos Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Glaukos Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, suggesting some underlying strength. However, both the Bollinger Bands and KST are bearish on the weekly and monthly, reinforcing the bearish sentiment. Moving averages are mildly bearish on the daily timeframe. In terms of performance, Glaukos Corp. has underperformed the S&P 500 over the past month and year, with returns of -1.67% and -34.77%, respectively, compared to the S&P 500's 1.92% and 19.89%. This highlights the stock's current weakness relative to the broader market....

Read More

Is Glaukos Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Glaukos Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by weekly MACD indicating mild bullishness but monthly MACD showing mild bearishness. The RSI is bullish on a monthly basis but shows no signal weekly. Bollinger Bands and KST are both mildly bearish across both time frames, and moving averages are mildly bearish on a daily basis. Additionally, the Dow Theory indicates no trend weekly and mildly bearish monthly. In terms of performance, Glaukos has significantly underperformed the S&P 500 year-to-date and over the past year, with returns of -41.72% and -33.68% respectively, compared to the S&P 500's gains of 16.30% and 19.89%. However, it has outperformed the benchmark over the 3-year period with a return of 81.08% versus 76.66%....

Read More

Is Glaukos Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Glaukos Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD being mildly bullish while the monthly MACD is mildly bearish. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly. Moving averages indicate a mildly bearish trend on the daily, and both the KST and OBV are bearish on the weekly and monthly. Dow Theory shows no trend on the weekly and mildly bearish on the monthly. In terms of multi-period returns, Glaukos has outperformed the S&P 500 over the past week and month, but it has significantly underperformed over the year-to-date and one-year periods. Overall, the mixed signals suggest caution in the current market environment....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
15.43%
EBIT Growth (5y)
4.55%
EBIT to Interest (avg)
-5.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.46
Tax Ratio
0.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.96
EV to EBIT
-49.44
EV to EBITDA
-80.62
EV to Capital Employed
10.78
EV to Sales
12.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-21.81%
ROE (Latest)
-15.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 93 Schemes (63.81%)

Foreign Institutions

Held by 152 Foreign Institutions (11.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 16.31% vs 1.14% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -8.84% vs 46.13% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "124.10",
          "val2": "106.70",
          "chgp": "16.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.10",
          "val2": "-11.40",
          "chgp": "-14.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.70",
          "val2": "-18.10",
          "chgp": "-8.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-182.80%",
          "val2": "-193.90%",
          "chgp": "1.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.86% vs 11.24% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.69% vs -35.79% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "383.50",
          "val2": "314.70",
          "chgp": "21.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-68.20",
          "val2": "-85.70",
          "chgp": "20.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "28.10",
          "val2": "13.60",
          "chgp": "106.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.20",
          "val2": "-5.00",
          "chgp": "-184.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-146.40",
          "val2": "-134.70",
          "chgp": "-8.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-282.00%",
          "val2": "-393.10%",
          "chgp": "11.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
124.10
106.70
16.31%
Operating Profit (PBDIT) excl Other Income
-13.10
-11.40
-14.91%
Interest
1.20
1.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.70
-18.10
-8.84%
Operating Profit Margin (Excl OI)
-182.80%
-193.90%
1.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 16.31% vs 1.14% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -8.84% vs 46.13% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
383.50
314.70
21.86%
Operating Profit (PBDIT) excl Other Income
-68.20
-85.70
20.42%
Interest
28.10
13.60
106.62%
Exceptional Items
-14.20
-5.00
-184.00%
Consolidate Net Profit
-146.40
-134.70
-8.69%
Operating Profit Margin (Excl OI)
-282.00%
-393.10%
11.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 21.86% vs 11.24% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.69% vs -35.79% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Glaukos Corp. stock-summary
stock-summary
Glaukos Corp.
Pharmaceuticals & Biotechnology
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Company Coordinates stock-summary
Company Details
229 Avenida Fabricante , SAN CLEMENTE CA : 92672-7531
stock-summary
Tel: 1 949 3679600
stock-summary
http://www.glaukos.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."